| Jessica L Weyer, MD | |
|
246 Pleasant St., Memorial Building, West, Floor 1, Concord, NH 03301-2548 | |
| (603) 228-1111 | |
| (603) 227-7558 |
| Full Name | Jessica L Weyer |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 246 Pleasant St., Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699154955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 19983 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Hospital Inc | 6103721790 | 462 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Recent media coverage on the challenges patients and families face with overtreatment of a life-limiting illness brings the issues of hospice and palliative care and advance care planning to public attention.
The Ministry of Health in Indonesia has confirmed an additional two cases of human infection with the H5N1 avian influenza virus.
› Verified 5 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Recent media coverage on the challenges patients and families face with overtreatment of a life-limiting illness brings the issues of hospice and palliative care and advance care planning to public attention.
The Ministry of Health in Indonesia has confirmed an additional two cases of human infection with the H5N1 avian influenza virus.
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Recent media coverage on the challenges patients and families face with overtreatment of a life-limiting illness brings the issues of hospice and palliative care and advance care planning to public attention.
The Ministry of Health in Indonesia has confirmed an additional two cases of human infection with the H5N1 avian influenza virus.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica L Weyer, MD 246 Pleasant St., Memorial Building, West, Floor 1, Concord, NH 03301-2548 Ph: (603) 228-1111 | Jessica L Weyer, MD 246 Pleasant St., Memorial Building, West, Floor 1, Concord, NH 03301-2548 Ph: (603) 228-1111 |
News Archive
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Recent media coverage on the challenges patients and families face with overtreatment of a life-limiting illness brings the issues of hospice and palliative care and advance care planning to public attention.
The Ministry of Health in Indonesia has confirmed an additional two cases of human infection with the H5N1 avian influenza virus.
› Verified 5 days ago
Rebecca Anne Ewing, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3 N State St, Concord, NH 03301 Phone: 603-225-0123 | |
Dr. David C. Conway, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 250 Pleasant Street, Yeaple Building, Concord, NH 03301 Phone: 603-228-7200 Fax: 603-228-7307 | |
Dr. Richard S Salchunas, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 189 N Main St, Concord, NH 03301 Phone: 603-228-1111 Fax: 603-226-4314 | |
Courtney Nicole Knill, MD Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 253 Pleasant St, Concord, NH 03301 Phone: 603-226-2200 | |
Dr. Elisabeth B Mayland, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 189 N Main St, Concord, NH 03301 Phone: 603-228-1111 Fax: 603-226-4314 | |
Mark Steven Kegel, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 246 Pleasant Street Memorial Building, West, Floor 1, Concord, NH 03301 Phone: 603-228-1111 Fax: 603-227-7558 | |
Dr. Courtney Brooke Jones, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 246 Pleasant Street Memorial Building, West, Floor 1, Concord, NH 03301 Phone: 603-228-1111 Fax: 603-226-4314 |